timothy sykes logo
MLYS Stock Climbs As FDA Review And New CLO Draw Trader Focus Thumbnail
G Google News

MLYS Stock Climbs As FDA Review And New CLO Draw Trader Focus

ELLIS HOBBS•UPDATED APR. 15, 2026, 5:04 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Mineralys Therapeutics Inc. stocks have been trading up by 13.47 percent amid investor optimism over its latest clinical developments

Candlestick Chart

Live Update At 17:03:55 EDT: On Wednesday, April 15, 2026 Mineralys Therapeutics Inc. stock [NASDAQ: MLYS] is trending up by 13.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MLYS has been trading like a biotech name gearing up for a major decision. Over the last few weeks, Mineralys Therapeutics stock has pushed from the low-$20s to above $30, with the most recent daily close at $30.42 after hitting an intraday high of $31.11. That is a sharp move from $22.88 on 2026/03/24, signaling traders are positioning around the lorundrostat FDA review story.

Intraday action on the latest session shows a tight grind higher. After a morning base in the $27s, MLYS pressed into the low $30s and held that range into the close, a sign of steady demand rather than a one-and-done spike. For active traders, that kind of controlled trend often matters more than any headline.

On the fundamentals, Mineralys Therapeutics is still a clinical‑stage biotech: no product revenue, negative earnings, heavy R&D. The latest quarterly report shows a net loss of about $32.3M and operating cash outflow near $37.9M. But the balance sheet is strong for a development story, with roughly $172.9M in cash and no debt, plus a sky‑high current ratio above 40. In simple terms, MLYS is burning cash but has a solid runway to get through the FDA decision and early launch planning.

Why Traders Are Watching MLYS Right Now

The core reason MLYS sits on so many watchlists is lorundrostat. Mineralys Therapeutics has taken this hypertension drug through multiple late‑stage trials, and the company now has a New Drug Application under FDA review. In biotech, that is the moment when the story moves from lab to real-world money. Approval or rejection can reprice a stock in one day, and traders know it.

Against that backdrop, the hiring of Jeffrey A. Munsie as Chief Legal Officer looks very intentional. Mineralys Therapeutics did not just pick any lawyer; they brought in a veteran biopharma counsel with experience in IP, contracts, compliance, and transactions. MLYS also granted him stock options and restricted stock units as an inducement. That aligns his upside with long‑term shareholder value and tells traders the company expects meaningful corporate activity ahead — think commercialization contracts, licensing, or even partnership talks if lorundrostat clears the FDA.

MLYS also disclosed inducement awards to a new non‑executive employee — 27,920 stock options and 20,940 RSUs under the 2025 Employment Inducement Incentive Award Plan. This is standard biotech playbook, but important. Mineralys Therapeutics is still staffing up for the next phase, even as it modestly dilutes the cap table. Traders should see this as part of building a launch‑ready organization, not a red flag by itself.

Layer on a fresh Form 4 showing insider activity in MLYS, and you have another magnet for short‑term trading. The filing simply confirms a change in beneficial ownership, but any insider move around a binary catalyst gets watched closely. Add CEO Jon Congleton joining Immunic’s board while staying at Mineralys Therapeutics, and the narrative becomes clearer: MLYS is led by an executive expanding his influence across biotech, likely adding relationships and information flow that can help Mineralys execute.

More Breaking News

Conclusion

For active traders, MLYS is a clean biotech catalyst setup wrapped in a strengthening corporate structure. The stock has already broken out from the low‑$20s to the $30 area as the market prices in the odds of lorundrostat approval. Mineralys Therapeutics now combines a strong cash pile, zero debt, and a late‑stage asset under FDA review, with a chart showing higher lows and solid intraday support.

The recent moves around management and equity awards fit that story. By appointing Jeffrey A. Munsie as Chief Legal Officer with stock‑based inducements, Mineralys Therapeutics is clearly gearing up for regulatory decisions, commercial contracts, and all the legal work that comes with turning a drug into a business. Additional inducement grants signal MLYS is still recruiting talent for that push. Insider trading activity via the Form 4 filing and Congleton’s board role at Immunic add extra layers for traders to track, especially around sentiment and perceived leadership strength.

The task for disciplined traders is simple: map out your scenarios, define risk, and avoid falling in love with the story. As Tim Sykes likes to say, “Trade the price action, not the hype — react to what the chart and volume are telling you, and always cut losses quickly.” That lines up with a core rule for short‑term trading psychology: don’t get emotionally attached to any single ticker. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. For MLYS, that means respecting both the upside of a favorable FDA outcome and the very real downside if the regulator says no, while using the news flow and technical levels as your guide. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading MLYS

Millionaire's
POV on MLYS

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”